Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Licenses Technology to Cellectricon

 

NEW YORK, April 14 - Gyros of Uppsala, Sweden has licensed one of its patents for microfluidics devices to Cellectricon, a developer of a microchip for drug discovery, the companies said today.

 

Cellectricon has used processes that are covered by the Gyros patent to develop its Dynaflow Microchip, a device for drug discovery.

 

The patent, "Microfluidic structure and process for its manufacture," was granted in the USin December 1994 (Patent No. 5,376,252), and also has corresponding worldwide patents, according to Gyros. It covers microfluidic structures with two stable base layers and an elastic spacer in between.

 

This new agreement is one of many that Gyros is pursuing, said company executives. Gyros recently announced a similar licensing agreement with Fluidigm, of South San Francisco, Calif.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.